| |
| |
|
| Insider
Information: |
Robinson Chandler |
| Relationship: |
Chief Executive Office... |
| City: |
Wilmette |
| State: |
IL |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
166,131 |
|
|
Indirect Shares
|
4,277,940 |
|
|
| Direct
Value |
$124,598 |
|
|
|
Indirect Value
|
$3,208,455 |
|
|
| Total
Shares |
4,444,071 |
|
|
| Total
Value |
$3,333,053 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Monopar Therapeutics |
MNPR |
Chief Executive Office... |
2024-03-31 |
166,131 |
2024-03-31 |
4,277,940 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2024-03-31 |
4 |
D |
$0.68 |
$4,884 |
D/D |
(7,172) |
166,131 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2024-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,474 |
173,303 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2024-01-01 |
4 |
D |
$0.34 |
$792 |
D/D |
(2,327) |
148,829 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2024-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,724 |
151,156 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2023-12-31 |
4 |
D |
$0.34 |
$2,881 |
D/D |
(8,469) |
144,432 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2023-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,474 |
152,901 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2023-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,474 |
135,599 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2023-09-30 |
4 |
D |
$0.62 |
$4,446 |
D/D |
(7,172) |
128,427 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2023-06-30 |
4 |
D |
$0.86 |
$8,780 |
D/D |
(10,269) |
111,125 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2023-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,039 |
121,394 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2023-01-01 |
4 |
D |
$2.37 |
$5,515 |
D/D |
(2,327) |
76,730 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2023-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,723 |
79,057 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2022-12-31 |
4 |
D |
$2.37 |
$11,409 |
D/D |
(4,814) |
72,334 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2022-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,912 |
77,148 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2022-09-30 |
4 |
D |
$1.52 |
$6,197 |
D/D |
(4,077) |
63,236 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2022-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,911 |
67,313 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2022-06-30 |
4 |
D |
$2.30 |
$16,091 |
D/D |
(6,999) |
53,402 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2022-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,882 |
60,401 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2022-03-31 |
4 |
D |
$2.55 |
$2,945 |
D/D |
(1,155) |
36,519 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2022-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,941 |
37,674 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,724 |
36,060 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2022-01-01 |
4 |
D |
$3.21 |
$7,470 |
D/D |
(2,327) |
33,733 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,941 |
30,700 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2021-12-31 |
4 |
D |
$3.21 |
$4,378 |
D/D |
(1,364) |
29,336 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Executive Officer |
• • – |
2021-09-30 |
4 |
D |
$4.87 |
$5,625 |
D/D |
(1,155) |
26,759 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
